Page 2 - Full Analysis Set News Today

Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, an important and long sought indicator of biochemical...

/PRNewswire/ -- vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases,...

- Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early - Significantly less aggressive critical care with maintained renal function in young adults -

/PRNewswire/ -- vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases,...

F. Hoffmann-La Roche Ltd: Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% Placebo Risk reduction 13 1.2 4 copies/mL) 14 0.4 * Individuals without any COVID-19 symptoms who lived in the same household as an individual who tested positive to SARS-CoV-2 within the prior four days . Based on the seronegative modified Full Analysis Set population, which includes al...

Share this article TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with imdevimab) 1,200 mg administere...

Met primary endpoint with robust statistical significance Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significance Showed statistically significant onset of action as early as week 2 Had a good safety and tolerability profile throughout the study Topline data confirm positive results from prior Phase IIa study in adults and Phase III studies of SPN-812 in children and adolescents ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) — Supernus Pha...